R. Clark

发表

Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems

R. Clark, 2000, Leukemia.

Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients

R. Clark, R. Clark, Robert J. Harris, 2015, Leukemia.

Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients

R. Clark, J. Grzybowski, D. Tidd, 1997, Leukemia.

Chronic Lymphocytic Leukaemia Developing in the Course of Chronic Myeloid Leukaemia

R. Clark, R. Clark, L. Wang, 2002, Leukemia & lymphoma.

DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS)

R. Clark, T. Hoy, A. Jacobs, 1986, British journal of haematology.

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

M. Pirmohamed, R. Clark, T. Holyoake, 2009, Leukemia.

Ras Mutations in Primary Myelodysplasia and in Patients Following Cytotoxic Therapy

D. Oscier, R. Clark, D. Bowen, 1989 .

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

W. Siegert, J. Lipton, D. Niederwieser, 2003, Leukemia.

Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis

M. Pirmohamed, R. Clark, S. Forchap, 2012, Leukemia.

Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes.

R. Clark, A. Jacobs, T. Hoy, 1985, Journal of clinical pathology.

Pathogenesis and clinical variations in the myelodysplastic syndromes.

R. Clark, A. Jacobs, 1986, Clinics in haematology.

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response

R. Clark, T. Holyoake, R. Clark, 2009, Leukemia.

Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia‐negative peripheral blood stem cells

R. Clark, A. Goldstone, A. Newland, 1997, British journal of haematology.

Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study

R. Clark, J. Rojas, L. Wang, 2007, Leukemia.

High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression

R. Kusec, J. Perry, R. Clark, 2010, Leukemia.

The effect of cytosine arabinoside on CFU-GM from patients with myelodysplastic syndrome.

R. Clark, A. Jacobs, R. Bailey‐Wood, 1987, Clinical and laboratory haematology.

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

R. Clark, L. Wang, N. Butt, 2008, Leukemia.

Dendritic cells become BCR–ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib

R. Clark, M. Atherton, L. Wang, 2004, Leukemia.

Primary myelodysplastic syndrome and cancer.

R. Clark, A. Jacobs, R. West, 1987, British medical journal.

Myelodysplastic syndrome in a kindred with ins(16) (p11.2)

R. Clark, A. Jacobs, K. Whittaker, 1988, Clinical genetics.

Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.

R. Clark, S. Wong, A. Pettitt, 1994, Bone marrow transplantation.

Analysis of BCR–ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype

M. Dyer, L. Foroni, G. Gerrard, 2010, Leukemia.

Isochromosome (6p) in Waldenstrom's macroglobulinemia.

A. D. White, R. Clark, A. Jacobs, 1992, Cancer genetics and cytogenetics.

Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation

R. Clark, L. Wang, A. Howarth, 2014, Leukemia.

Prognostic importance of hypodiploid hemopoietic precursors in myelodysplastic syndromes.

R. Clark, A. Jacobs, S. Peters, 1986, The New England journal of medicine.

BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis

J. Melo, R. Clark, L. Wang, 2003, Leukemia.

Differences in bone marrow cytogenetic characteristics between treated and untreated myeloma.

R. Clark, J. Whittaker, A. Jacobs, 1989, European journal of cancer & clinical oncology.

European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching

M. Labopin, A. Nagler, J. Reiffers, 1997, Bone Marrow Transplantation.

A randomized trial of 13‐cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome

R. Clark, A. Jacobs, H. Payne, 1987, British journal of haematology.

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease

T. Brümmendorf, P. Cony-Makhoul, M. Copland, 2020, Leukemia.

Clonal haemopoiesis following cytotoxic therapy for lymphoma.

R. Clark, J. Whittaker, A. Jacobs, 1993, Leukemia.

EFFECT OF 13-cis-RETINOIC ACID ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME

R. Clark, A. Jacobs, C. Lush, 1987, The Lancet.

Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

E. Havrdová, R. Clark, A. Steck, 2006, Multiple sclerosis.

High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia

M. Butterworth, R. Clark, C. Lucas, 2016, Leukemia.

High CIP 2 A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia

M. Butterworth, R. Clark, C. Lucas, 2016 .

e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts

R. Clark, L. Wang, J. Seale, 2002, Leukemia.

Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid.

R. Clark, A. Jacobs, S. Smith, 1987, Journal of Clinical Pathology.

The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation

A. Nagler, D. Niederwieser, T. Witte, 2008, Bone Marrow Transplantation.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

M. Baccarani, G. Rosti, K. Porkka, 2016, Leukemia.

Chromosome aberrations following cytotoxic therapy in patients in complete remission from lymphoma.

A. D. White, R. Clark, A. Jacobs, 1992, Carcinogenesis.

RAS mutations in patients following cytotoxic therapy for lymphoma.

F. McCormick, R. Clark, J. Whittaker, 1990, Oncogene.